TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1770147

Group type: COMPARATOR
Intervention: Expectant management (n = 16)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Medical treatment (n = 33) using transvaginal methotrexate or sulprostone injection
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall follow-up for all patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography
Number of subjects: 49
Study: 6982085

Group type: EXPERIMENTAL
Intervention: Modified LSA2‐L2 multidrug regimen
Number of subjects: 53
Study: 30285104

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 8 weeks
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 29277297

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and isoflurane (Dex-Iso, n = 50)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Isoflurane alone (Iso, n = 47)
Number of subjects: 97
Study: 27782847

Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing
Number of subjects: 284

Group type: COMPARATOR
Intervention: Basic clinical assessment with noninvasive tests
Number of subjects: 284
Study: 24886449

Group type: EXPERIMENTAL
Intervention: Combined wound and intraperitoneal local anesthetic (W + P)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No local wound anesthetic with intraperitoneal local anesthetic (NW + P)
Number of subjects: 220
Study: 23585468

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral psychotherapy combined with intramuscular (IM) 3‐monthly injections of triptorelin for 12 months (total of 4 injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with cognitive‐behavioral psychotherapy for 12 months (total of 4 injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral psychotherapy combined with triptorelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with cognitive‐behavioral psychotherapy
Number of subjects: 0
Study: 20573223

Group type: EXPERIMENTAL
Intervention: Lithium + Valproic Acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium + Carbamazepine
Number of subjects: 0
Study: 18277375

Group type: EXPERIMENTAL
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group A
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group B1
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1 L/d placebo mineral water (Ca:80 mg/L) for Group B2
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group B2 (after switching from placebo)
Number of subjects: 95
Study: 15681008

Group type: EXPERIMENTAL
Intervention: Self-etching primer for 20 s (Clearfil SE Primer) with Single Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 M EDTA for 30 s with Clearfil SE Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid for 15 s with Single Bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other combinations (not specified)
Number of subjects: 0
Study: 14618354

Group type: EXPERIMENTAL
Intervention: Sekundo's slitlamp green light test
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colvard pupilometer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of methods
Number of subjects: 50
Study: 10561363

Group type: EXPERIMENTAL
Intervention: IFNalpha2a plus VLB
Number of subjects: 160

Group type: COMPARATOR
Intervention: VLB alone
Number of subjects: 160
Study: 8970247

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 926

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 926
Study: 1468826

Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg per day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 6504945

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg twice daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg twice daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Both doses of pivmecillinam
Number of subjects: 292
Study: 30940355

Group type: EXPERIMENTAL
Intervention: Local infiltration injections
Number of subjects: 100

Group type: COMPARATOR
Intervention: Infraorbital nerve block
Number of subjects: 100
Study: 29034453

Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan nasal powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral sumatriptan (100 mg tablets)
Number of subjects: 0
Study: 27454274

Group type: EXPERIMENTAL
Intervention: IV dexamethasone 0.5 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caudal dexamethasone 0.1 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (IV normal saline)
Number of subjects: 90
Study: 24823727

Group type: EXPERIMENTAL
Intervention: Drain group (subdural drain inserted after burr-hole drainage)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Without drain group (no subdural drain inserted after burr-hole drainage)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Without drain group
Number of subjects: 200
Study: 23193843

Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAAs)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 20618100

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided access with the patient in the flank position (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoroscopy-guided access with the patient in the prone position (Group 2)
Number of subjects: 60
Study: 18396107

Group type: EXPERIMENTAL
Intervention: Early intensive lowering of blood pressure (target systolic BP 140 mm Hg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard guideline-based management of blood pressure (target systolic BP 180 mm Hg)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Early intensive lowering of blood pressure
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard guideline-based management of blood pressure
Number of subjects: 404
Study: 15573384

Group type: EXPERIMENTAL
Intervention: University of Wisconsin symptom scale (WICS) for IC patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: University of Wisconsin symptom scale (WICS) for healthy female controls
Number of subjects: 30
Study: 12008175

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 10493455

Group type: EXPERIMENTAL
Intervention: Head and neck cooling using a Life Support Systems, Inc. Mark VII portable cooling system and a liquid cooling helmet for 30 minutes.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Head and neck cooling during winter studies.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Head and neck cooling during summer studies for male subjects.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Head and neck cooling during summer studies for female subjects.
Number of subjects: 50
Study: 9199122

Group type: EXPERIMENTAL
Intervention: Program I - Individual, motivating instructions of tooth brushing with bacterial plaque coloring
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Program II - Expanded educational activity among children and parents
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Program III - Expanded educational activity and professional cleaning of teeth, sealing, and intensive conservative treatment
Number of subjects: 255
Study: 8293692

Group type: EXPERIMENTAL
Intervention: Low dose aspirin 75 mg/day (study group, n = 40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (control group, n = 44)
Number of subjects: 84
Study: 3565526

Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control hand (no splinting)
Number of subjects: 19
Study: 31924234

Group type: EXPERIMENTAL
Intervention: Custodiol‐N
Number of subjects: 614

Group type: COMPARATOR
Intervention: Custodiol®
Number of subjects: 614
Study: 29360493

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study: 27590263

Group type: EXPERIMENTAL
Intervention: B. catenulatum at 3 months
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: B. breve at 1 week
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: B. breve at 3 months
Number of subjects: 117
Study: 25817050

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 0
Study: 23609777

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (daily oral Zn supplements for two months)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 2
Study: 21787433

Group type: EXPERIMENTAL
Intervention: PUFAS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Naltrexone + PUFAS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19543667

Group type: EXPERIMENTAL
Intervention: Superficial warmth (42 degrees C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preference for warmth therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preference for transcutaneous electrical nerve stimulation
Number of subjects: 32
Study: 16936149

Group type: EXPERIMENTAL
Intervention: Intravenous C‐peptide infusion (dosage 1: 25 pmol . kg(‐1) . min(‐1) bolus followed by 5 pmol . kg(‐1) . min(‐1) continuous infusion; dosage 2: six times higher than dosage 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiologic saline solution (control)
Number of subjects: 10
Study: 15238460

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 12 months
Number of subjects: 40
Study: 11182002

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with vinorelbine, paclitaxel, or gemcitabine plus cisplatin followed by concomitant chemoradiotherapy with the same agents and standard radiation (66 Gy)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Accelerated radiotherapy
Number of subjects: 187
Study: 10221358

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 50-200 mg daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 41
Study: 8032080

Group type: EXPERIMENTAL
Intervention: Various premedications (Groups A, B, C, D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray (Groups A and C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (C1, C2, C3) - non‐diabetic patients not endoscoped
Number of subjects: 120
Study: 2480941

Group type: EXPERIMENTAL
Intervention: Fractionated regimen of 2500‐3000 cGy in 9 to 10 fractions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Single dose of 600 cGy or 800 cGy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fractionated regimen
Number of subjects: 29

Group type: COMPARATOR
Intervention: Single dose therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 4866185

Group type: EXPERIMENTAL
Intervention: Pyridoxine 6 mg daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pyridoxine 6 mg or 48 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: High-dosage isoniazid
Number of subjects: 3
Study: 29389068

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 26560898

Group type: EXPERIMENTAL
Intervention: Atopic asthma
Number of subjects: 546

Group type: COMPARATOR
Intervention: Nonatopic asthma
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: High total IgE (tIgE)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Low total IgE (tIgE)
Number of subjects: 546
Study: 24630791

Group type: EXPERIMENTAL
Intervention: Continue group (n = 86)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Hold group (n = 86)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: No DM group (n = 25)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Continue group (n = 25)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Hold group (n = 25)
Number of subjects: 172
Study: 22933750

Group type: COMPARATOR
Intervention: Boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Boiled orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fried orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Number of subjects: 120

Group type: COMPARATOR
Intervention: Boiled white-fleshed sweet potatoes (WFSP) and a retinyl palmitate capsule
Number of subjects: 120
Study: 20505660

Group type: EXPERIMENTAL
Intervention: 400 mg modafinil (divided into three doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18726829

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Metformin (2000 mg daily)
Number of subjects: 463
Study: 15733508

Group type: EXPERIMENTAL
Intervention: Computerized limited asthma education program (30-min interactive program + 30-min discussion with asthma nurse)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine schedule for asthma outpatients (Control)
Number of subjects: 97
Study: 12843214

Group type: COMPARATOR
Intervention: SPECT imaging after intravenous injection of hexamethylpropyleneamine oxime or ethylcysteinate dimer
Number of subjects: 29

Group type: COMPARATOR
Intervention: SPECT imaging in LS+ patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SPECT imaging in LS+ vs LS- patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: SPECT imaging in A- patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SPECT imaging in A+ vs A- patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SPECT imaging in patients without atrophy
Number of subjects: 29
Study: 10228126

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2223528

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diuretic (half-strength Moduretic: hydrochlorothiazide 25 mg + amiloride hydrochloride 2.5 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of atenolol, hydrochlorothiazide, and amiloride hydrochloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active treatment (atenolol or diuretic)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: 24-hour ambulatory ECG monitoring
Number of subjects: 27
Study: 80275

Group type: EXPERIMENTAL
Intervention: Adriamycin (60 mg/m2 every 3 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bleomycin (15 mg/m2 weekly)
Number of subjects: 27
Study: 31944127

Group type: EXPERIMENTAL
Intervention: Audio Processor Satisfaction Questionnaire (APSQ)
Number of subjects: 69
Study: 31533379

Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 40
Study: 27987221

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 27
Study: 26502714

Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (AA)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both AA and AL
Number of subjects: 248
Study: 23810029

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (n=282)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Mail questionnaire (n=277)
Number of subjects: 559
Study: 21060109

Group type: EXPERIMENTAL
Intervention: IDX184 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX184 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX184 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX184 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX184 75 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX184 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19597358

Group type: EXPERIMENTAL
Intervention: Self‐Focused Exposure Therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cognitive and behavioral method
Number of subjects: 30
Study: 17313720

Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 15 mg/d for 6 months
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 30 mg/d for 6 months
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 15108100

Group type: EXPERIMENTAL
Intervention: Amphotericin B oral suspension
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 40
Study: 11772795

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9690694

Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7861714

Group type: EXPERIMENTAL
Intervention: 5 mg/day s.c. of recombinant human growth hormone (rhGH) during the treatment period
Number of subjects: 10
Study: 2524603

Group type: EXPERIMENTAL
Intervention: Moxisylyte
Number of subjects: 170

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 170
Study: 393464

Group type: EXPERIMENTAL
Intervention: fenbufen (800 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: indomethacin (100 mg/day)
Number of subjects: 29
Study: 31011865

Group type: EXPERIMENTAL
Intervention: Real 850-nm PBM by LED array on the right prefrontal cortex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 28153927

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Computer skills training (CST) placebo
Number of subjects: 27
Study: 26482669

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy screen visible to the instructor
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (videolaryngoscope screen covered)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with premedication
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group with premedication (screen covered)
Number of subjects: 206
Study: 23679192

Group type: EXPERIMENTAL
Intervention: Toremifene 120 mg (TOR120)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Exemestane 25 mg (EXE)
Number of subjects: 91
Study: 22095792

Group type: EXPERIMENTAL
Intervention: rLH
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control (rFSH alone)
Number of subjects: 244
Study: 20952373

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (e.g., statins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low total cholesterol (<5.5 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (statins)
Number of subjects: 0
Study: 18020846

Group type: EXPERIMENTAL
Intervention: Couple-focused group intervention (CG) for women with early stage breast cancer, 6 sessions
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Couple-focused group intervention (CG)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 238
Study: 16132121

Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented beverage (30 ml.kg(‐1) pre-exercise and during exercise)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (30 ml.kg(‐1) pre-exercise and during exercise)
Number of subjects: 26
Study: 12189360

Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: indinavir
Number of subjects: 176

Group type: COMPARATOR
Intervention: saquinavir
Number of subjects: 176
Study: 10434218

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 or 0.2 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rocuronium (0.9 or 1.2 mg/kg)
Number of subjects: 40
Study: 7843700

Group type: COMPARATOR
Intervention: Interferon (IFN) therapy for 6 months (3 to 5 million units three times a week)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy for 6 months (IFN) and 3 additional months (UDCA 10 mg/kg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interferon (IFN) therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 80
Study: 2222595

Group type: EXPERIMENTAL
Intervention: Nebulized isoetharine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Basic life support only (Control)
Number of subjects: 52
Study: 6993163

Group type: EXPERIMENTAL
Intervention: Insulin therapy during pregnancy
Number of subjects: 615

Group type: COMPARATOR
Intervention: Control group (no insulin therapy)
Number of subjects: 615
Study: 31884472

Group type: EXPERIMENTAL
Intervention: T3D-959 (3, 10, 30, or 90 mg daily for 14 days)
Number of subjects: 34
Study: 31796480

Group type: EXPERIMENTAL
Intervention: QinTB smartphone application
Number of subjects: 400

Group type: COMPARATOR
Intervention: Doctors' advice
Number of subjects: 400
Study: 28347654

Group type: EXPERIMENTAL
Intervention: Alirocumab 75mg every 2 weeks (Q2W)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Alirocumab 150mg Q2W (for those with LDL-C≥70mg/dL at week 8)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 25758408

Group type: EXPERIMENTAL
Intervention: Six 1‐h circuit classes targeting balance over a 2‐week period in addition to usual therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 162